News

CDVAX Partnership

FGK is partner of the CDVAX project funded under the European Union 7th Framework

CDVAX is a project funded under the European Union 7th Framework Programme. The aim of CDVAX is to take forward a novel and highly innovative oral vaccine that will provide protection against Clostridium difficile infection. This novel approach will use the spores of a genetically engineered harmless bacteria to generate a vaccine to protect vulnerable patients against this serious and life threatening hospital acquired infection. This project will develop the vaccine and evaluate it in a human clinical trial.